<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Euroapi Sa — News on 6ix</title>
    <link>https://6ix.com/company/euroapi-sa</link>
    <description>Latest news and press releases for Euroapi Sa on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 16 Dec 2025 16:47:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/euroapi-sa" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d53044beedb30cb6f6cf8f.webp</url>
      <title>Euroapi Sa</title>
      <link>https://6ix.com/company/euroapi-sa</link>
    </image>
    <item>
      <title>Market update</title>
      <link>https://6ix.com/company/euroapi-sa/news/market-update-201</link>
      <guid isPermaLink="true">https://6ix.com/company/euroapi-sa/news/market-update-201</guid>
      <pubDate>Tue, 16 Dec 2025 16:47:00 GMT</pubDate>
      <description>Press Release Paris – December 16, 2025 - EUROAPI announced today that its main shareholders, Sanofi and EPIC Bpifrance, have agreed to extend further the duration of their lock-up until December 18, 2026, subject to customary exceptions. This extension strengthens the stability of EUROAPI’s shareholding structure throughout the execution of its FOCUS-27 plan. Based on its latest forecast, EUROAPI also provided the following business update: In a deteriorated overall business environment, Full Y</description>
    </item>
    <item>
      <title>Tristan Imbert co-opted as Independent Director</title>
      <link>https://6ix.com/company/euroapi-sa/news/tristan-imbert-co-opted-as-independent-director-1</link>
      <guid isPermaLink="true">https://6ix.com/company/euroapi-sa/news/tristan-imbert-co-opted-as-independent-director-1</guid>
      <pubDate>Wed, 10 Dec 2025 16:45:00 GMT</pubDate>
      <description>Press Release Paris – December 10, 2025 - EUROAPI today announces that, following the resignation of Rodolfo Savitzky from his position as Independent Director (effective December 31, 2025)1, and upon the recommendation of the Nominations and Compensation Committee, the Board of Directors has decided to co-opt Tristan Imbert as Independent Director, subject to the vote of EUROAPI Shareholders’ meeting on May 27, 2026. Tristan Imbert will be appointed Chair of the Audit Committee, effective Janua</description>
    </item>
    <item>
      <title>With Med4Cure, EUROAPI accelerates pharmaceutical innovation at the service of health sovereignty</title>
      <link>https://6ix.com/company/euroapi-sa/news/with-med4cure-euroapi-accelerates-pharmaceutical-innovation-at-the-service-of-health-sovereignty-1</link>
      <guid isPermaLink="true">https://6ix.com/company/euroapi-sa/news/with-med4cure-euroapi-accelerates-pharmaceutical-innovation-at-the-service-of-health-sovereignty-1</guid>
      <pubDate>Thu, 23 Oct 2025 15:45:00 GMT</pubDate>
      <description>Press Release The project launch event, held at the Vertolaye site, brought together State officials, elected representatives, and several project partners to accelerate pharmaceutical innovation in Europe Paris – October 23, 2025 – EUROAPI officially launched its innovation programs today as part of the Health IPCEI (Important Project of Common European Interest), a European initiative aimed at strengthening pharmaceutical sovereignty. This project, called “Med4Cure,” is supported by the Europe</description>
    </item>
    <item>
      <title>Change in Board’s Composition</title>
      <link>https://6ix.com/company/euroapi-sa/news/change-in-boards-composition-1</link>
      <guid isPermaLink="true">https://6ix.com/company/euroapi-sa/news/change-in-boards-composition-1</guid>
      <pubDate>Tue, 30 Sep 2025 15:45:00 GMT</pubDate>
      <description>Press Release Paris – September 30, 2025 - EUROAPI today announces that, in line with best governance’s practices, and following his appointment as Recipharm’s Chief Financial Officer, effective October 1st, 2025, Rodolfo J. Savitzky will step down from his role as EUROAPI’s Independent Director and Chair of the Audit Committee, effective December 31, 2025. The search for a new Independent Director has been initiated, and Rodolfo J. Savitzky’s successor is expected to be appointed before the end</description>
    </item>
    <item>
      <title>Science Based Targets initiative (SBTi) validates EUROAPI’s near-term climate targets</title>
      <link>https://6ix.com/company/euroapi-sa/news/science-based-targets-initiative-sbti-validates-euroapis-near-term-climate-targets-1</link>
      <guid isPermaLink="true">https://6ix.com/company/euroapi-sa/news/science-based-targets-initiative-sbti-validates-euroapis-near-term-climate-targets-1</guid>
      <pubDate>Thu, 18 Sep 2025 05:00:00 GMT</pubDate>
      <description>Press Release 42% reduction in Scope 1 and 2 Greenhouse Gas emissions by 2030 (vs. 2022)25% reduction in Scope 3 GHG emissions by 2030 (vs. 2022) September 18, 2025 - EUROAPI’s near-term science-based emission reduction targets have been approved by the Science Based Targets initiative (SBTi1), confirming the company’s alignment with the Paris Agreement trajectory of limiting global warming to 1.5°C above pre-industrial levels. EUROAPI commits to reduce absolute Scope 1 and 2 greenhouse gas (GHG</description>
    </item>
    <item>
      <title>Availability of 2025 Half-Year Financial Report</title>
      <link>https://6ix.com/company/euroapi-sa/news/availability-of-2025-half-year-financial-report-1</link>
      <guid isPermaLink="true">https://6ix.com/company/euroapi-sa/news/availability-of-2025-half-year-financial-report-1</guid>
      <pubDate>Thu, 31 Jul 2025 16:30:00 GMT</pubDate>
      <description>Press Release Paris – July 31, 2025 – EUROAPI posted today its 2025 condensed Half-Year Consolidated Financial Statements for the six months ended June 30, 2025. This document is available for consultation and downloading on EUROAPI’s website: https://www.euroapi.com/en/investors/regulatory-information/financial-reports. This report includes notably the 2025 half-year management report, the consolidated financial statements on 30 June 2025, and the Statutory Auditors’ review report on the half-y</description>
    </item>
    <item>
      <title>First-half 2025 results</title>
      <link>https://6ix.com/company/euroapi-sa/news/first-half-2025-results-1</link>
      <guid isPermaLink="true">https://6ix.com/company/euroapi-sa/news/first-half-2025-results-1</guid>
      <pubDate>Tue, 29 Jul 2025 16:42:00 GMT</pubDate>
      <description>Press Release Paris, 29th July 2025 7% to 9% 2025 Core EBITDA margin guidance reaffirmed, with ambition to be in the upper part of the range, supported by thorough execution of the FOCUS-27 plan, and despite more challenging topline €412.1 million Net Sales (- 8.2% year-on-year) Challenging year-on-year comparison, primarily due to a €21 million one off in H1 2024, excluding this exceptional impact, sales would have declined by 4% EBITDA at €5.0 million compared to €(1.4) million in H1 2024 Core</description>
    </item>
    <item>
      <title>EUROAPI sells Haverhill site to Particle Dynamics as part of its FOCUS-27 transformation plan</title>
      <link>https://6ix.com/company/euroapi-sa/news/euroapi-sells-haverhill-site-to-particle-dynamics-as-part-of-its-focus-27-transformation-plan</link>
      <guid isPermaLink="true">https://6ix.com/company/euroapi-sa/news/euroapi-sells-haverhill-site-to-particle-dynamics-as-part-of-its-focus-27-transformation-plan</guid>
      <pubDate>Mon, 30 Jun 2025 15:58:00 GMT</pubDate>
      <description>Press Release Paris – June 30, 2025 – EUROAPI today announced the signing of a share purchase agreement (SPA) for the sale of 100% of EUROAPI UK Ltd, the subsidiary operating its Haverhill manufacturing site, with a simultaneous closing to Particle Dynamics - a global leader in particle processing, delivery technologies, and finished dose manufacturing for the nutraceutical, consumer health, and pharmaceutical sectors. “The divestment of Haverhill is a key step toward optimizing our industrial f</description>
    </item>
    <item>
      <title>Frédéric Robert appointed EUROAPI’s Chief Commercial Officer overseeing API Solutions and CDMO activities</title>
      <link>https://6ix.com/company/euroapi-sa/news/frederic-robert-appointed-euroapis-chief-commercial-officer-overseeing-api-solutions-and-cdmo-activities-1</link>
      <guid isPermaLink="true">https://6ix.com/company/euroapi-sa/news/frederic-robert-appointed-euroapis-chief-commercial-officer-overseeing-api-solutions-and-cdmo-activities-1</guid>
      <pubDate>Wed, 04 Jun 2025 15:45:00 GMT</pubDate>
      <description>Press Release Paris – June 4, 2025 – EUROAPI, a European leader in the production of active pharmaceutical ingredients (API) and contract development and manufacturing organization (CDMO), is pleased to announce the appointment of Frédéric Robert to the newly created position of Chief Commercial Officer overseeing API Solutions and CDMO activities. He will join the company’s Executive Committee. This appointment is part of EUROAPI’s ongoing FOCUS-27 transformation plan and reinforces its positio</description>
    </item>
    <item>
      <title>Combined General Meeting of May 21, 2025</title>
      <link>https://6ix.com/company/euroapi-sa/news/combined-general-meeting-of-may-21-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/euroapi-sa/news/combined-general-meeting-of-may-21-2025-1</guid>
      <pubDate>Wed, 21 May 2025 15:45:00 GMT</pubDate>
      <description>Press Release - Approval of all resolutions submitted by the Board of Directors, including the unconsolidated and consolidated financial statements for the year 2024 - Paris – May 21, 2025 – The Combined General Shareholders’ Meeting of EUROAPI was held on May 21, 2025 in Paris, under the chairmanship of Emmanuel Blin. All resolutions put forth to a vote were adopted by the shareholders. The General Meeting approved the unconsolidated and consolidated financial statements for the year 2024, all</description>
    </item>
    <item>
      <title>Combined General Meeting of May 21, 2025 - Availability of preparatory documents</title>
      <link>https://6ix.com/company/euroapi-sa/news/combined-general-meeting-of-may-21-2025-availability-of-preparatory-documents</link>
      <guid isPermaLink="true">https://6ix.com/company/euroapi-sa/news/combined-general-meeting-of-may-21-2025-availability-of-preparatory-documents</guid>
      <pubDate>Tue, 29 Apr 2025 15:40:00 GMT</pubDate>
      <description>Press Release Paris – April 29, 2025 – EUROAPI’s shareholders are invited to attend the Combined General Meeting to be held on Wednesday May 21, 2025 at 10:30 a.m. (CET) at 15 bis, rue Traversière 75012 Paris. The notice of meeting was published at the French official legal announcement publication (BALO) on Wednesday April 16, 2025 and the convening notice (avis de convocation) was published in the Actu-juridique.fr, a French journal of legal notice, on April 28, 2025. The documents and informa</description>
    </item>
  </channel>
</rss>